Novavax (NVAX) Income from Continuing Operations (2010 - 2026)

Novavax's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 9491000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 101.83% year-over-year to 9491000.0; the TTM figure through Mar 2026 stood at 87835000.0 (down 118.35% YoY), while the FY2025 annual figure was 440302000.0, up 334.83% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 9491000.0, down from 17527000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 518646000.0 in Q1 2025, with the low at 510485000.0 in Q2 2022.
• The 5-year median for Income from Continuing Operations is 121300000.0 (2024), against an average of 56452294.12.
• The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations sank 244.49% in 2023, then surged 451.51% in 2025.
• Novavax's Income from Continuing Operations stood at 182249000.0 in 2022, then increased by 2.12% to 178389000.0 in 2023, then soared by 54.58% to 81030000.0 in 2024, then soared by 121.63% to 17527000.0 in 2025, then tumbled by 154.15% to 9491000.0 in 2026.
• Business Quant data shows NVAX's Income from Continuing Operations at 9491000.0 in Q1 2026, 17527000.0 in Q4 2025, and 202379000.0 in Q3 2025.